Hospital
Uch-Mhs
Uch-Mhs was paid $69.18M by Medicaid between Jan 2018 and Dec 2024, across 266 billing codes. Its largest line is 99212, Office or other outpatient visit for the evaluation and management of an established patient, straightforward — 20% of everything it billed.
33Billing provider infoUCH-MHS
COLORADO SPRINGS, CO 80909
COLORADO SPRINGS, CO 80909
33aNPI1144397134assigned 11/29/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$69.18M
24GClaims1,373,077
24DCodes billed266
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Colorado
Rank by total paid#3 of 51
Median peer was paid$1.24M
This provider vs. median56×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 223,360 | $10.97M | |
| 2019 | 169,148 | $8.72M | |
| 2020 | 138,184 | $6.36M | |
| 2021 | 216,738 | $9.22M | |
| 2022 | 241,707 | $12.97M | |
| 2023 | 223,140 | $11.97M | |
| 2024incomplete | 160,800 | $8.97M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 20% | 116,619 | 110,520 | $13.74M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 19% | 113,898 | 104,285 | $13.15M |
| 96361 | Intravenous infusion, hydration; each additional hour | 13% | 33,877 | 29,732 | $8.79M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 60,674 | 56,359 | $7.09M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.9% | 36,703 | 34,055 | $4.09M |
| G0378 | Hospital observation service, per hour | 4.4% | 15,405 | 12,849 | $3.05M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.1% | 23,874 | 22,543 | $2.13M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 3.0% | 17,538 | 16,654 | $2.04M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.2% | 29,579 | 25,349 | $1.56M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.6% | 13,338 | 12,802 | $1.10M |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.1% | 78,295 | 71,270 | $738K |
| 80047 | 1.0% | 36,505 | 33,055 | $726K |
254 more codes
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.0% | 3,811 | $693K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,645 | $649K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 21,072 | $556K |
| J2357 | Injection, omalizumab, 5 mg | <1% | 628 | $533K |
| 95811 | <1% | 726 | $515K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 654 | $486K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,443 | $439K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,236 | $359K |
| 0002A | <1% | 3,956 | $349K | |
| 80053 | Comprehensive metabolic panel | <1% | 21,247 | $338K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,767 | $319K |
| 80076 | <1% | 24,052 | $318K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 20,227 | $291K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 2,629 | $260K |
| 84484 | <1% | 14,428 | $257K | |
| 0001A | <1% | 2,882 | $250K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 330 | $239K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,559 | $233K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,859 | $221K |
| 64483 | <1% | 288 | $157K | |
| 59025 | Fetal non-stress test | <1% | 996 | $155K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 144,883 | $145K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 4,897 | $132K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,574 | $129K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 97 | $125K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 88 | $122K |
| 62323 | <1% | 285 | $117K | |
| 73564 | <1% | 1,523 | $117K | |
| 96402 | <1% | 489 | $113K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 8,051 | $111K |
| 93296 | <1% | 5,406 | $97K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 12,045 | $96K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 136 | $91K |
| 36415 | Collection of venous blood by venipuncture | <1% | 33,074 | $81K |
| 93798 | <1% | 1,099 | $79K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,869 | $74K |
| 0004A | <1% | 1,061 | $73K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 119 | $66K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,933 | $62K |
| 81001 | <1% | 19,666 | $60K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 327 | $60K |
| 73610 | <1% | 824 | $59K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 333 | $57K |
| 95812 | <1% | 229 | $51K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 41,160 | $49K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 491 | $45K |
| 97602 | <1% | 199 | $43K | |
| 73130 | <1% | 459 | $40K | |
| 73630 | <1% | 633 | $38K | |
| 73030 | <1% | 471 | $38K | |
| 96401 | <1% | 276 | $37K | |
| 93017 | <1% | 378 | $36K | |
| 52356 | <1% | 14 | $33K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 276 | $32K |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 853 | $30K |
| 87522 | Neg quan hep c or qual rna | <1% | 527 | $30K |
| 83605 | <1% | 1,048 | $30K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,104 | $30K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 59,680 | $28K |
| J0248 | Injection, remdesivir, 1 mg | <1% | 98 | $24K |
| 97803 | <1% | 150 | $23K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,977 | $22K |
| 97802 | <1% | 127 | $22K | |
| 86769 | <1% | 520 | $22K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 983 | $20K |
| 82043 | <1% | 279 | $20K | |
| J3490 | Unclassified drugs | <1% | 110,753 | $19K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 24 | $19K |
| 73502 | <1% | 237 | $18K | |
| 80320 | <1% | 190 | $18K | |
| 94726 | <1% | 235 | $18K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,112 | $17K |
| 80061 | Lipid panel | <1% | 828 | $17K |
| 88142 | <1% | 1,103 | $16K | |
| 85027 | <1% | 1,753 | $12K | |
| 93297 | <1% | 523 | $12K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 141 | $11K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,530 | $11K |
| 0064A | <1% | 144 | $11K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 205 | $11K |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 1,651 | $10K |
| 84439 | <1% | 2,117 | $10K | |
| 0003A | <1% | 108 | $10K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,020 | $10K |
| 86140 | <1% | 279 | $10K | |
| 87081 | <1% | 4,189 | $9K | |
| 73110 | <1% | 101 | $9K | |
| 0124A | <1% | 263 | $8K | |
| 0012A | <1% | 94 | $8K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 666 | $8K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 22,528 | $8K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 27 | $8K |
| 87510 | <1% | 319 | $7K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 89 | $7K |
| 86850 | <1% | 203 | $7K | |
| 94060 | <1% | 177 | $7K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 164 | $7K |
| 72170 | <1% | 71 | $6K | |
| 72110 | <1% | 75 | $6K | |
| 0054A | <1% | 200 | $6K | |
| 87150 | <1% | 149 | $6K | |
| 96367 | <1% | 71 | $6K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 32 | $6K |
| 81003 | <1% | 13,819 | $6K | |
| 94729 | <1% | 237 | $5K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 173 | $5K |
| 73100 | <1% | 72 | $5K | |
| 86256 | <1% | 117 | $5K | |
| 73562 | <1% | 100 | $4K | |
| 43235 | <1% | 14 | $4K | |
| 73140 | <1% | 50 | $4K | |
| 85610 | <1% | 822 | $4K | |
| 71045 | Radiologic examination, chest; single view | <1% | 9,243 | $4K |
| 93299 | <1% | 173 | $4K | |
| 93971 | <1% | 16 | $4K | |
| 87660 | <1% | 319 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,618 | $4K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,688 | $4K |
| 80143 | <1% | 36 | $3K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 152 | $3K |
| 82784 | <1% | 146 | $3K | |
| 83690 | <1% | 11,844 | $3K | |
| 97165 | <1% | 40 | $3K | |
| Q0222 | Injection, bebtelovimab, 175 mg | <1% | 31 | $3K |
| 73501 | <1% | 58 | $3K | |
| 83516 | <1% | 71 | $3K | |
| 94010 | <1% | 63 | $3K | |
| 82746 | <1% | 90 | $3K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,570 | $3K |
| 87340 | <1% | 172 | $2K | |
| 84480 | <1% | 366 | $2K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 12 | $2K |
| 81025 | <1% | 4,846 | $2K | |
| 80306 | <1% | 6,826 | $2K | |
| 84466 | <1% | 158 | $2K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 56 | $2K |
| 81511 | <1% | 26 | $2K | |
| 85652 | <1% | 309 | $2K | |
| 0071A | <1% | 19 | $2K | |
| 0072A | <1% | 18 | $2K | |
| 84156 | <1% | 281 | $2K | |
| C9399 | Unclassified drugs or biologicals | <1% | 161 | $2K |
| 86003 | <1% | 64 | $2K | |
| 86762 | <1% | 104 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 41 | $2K |
| 0352U | <1% | 398 | $2K | |
| 0013A | <1% | 16 | $2K | |
| 80179 | <1% | 33 | $2K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 150 | $1K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 17 | $1K |
| 82607 | <1% | 109 | $1K | |
| 86780 | <1% | 139 | $1K | |
| 82248 | <1% | 173 | $1K | |
| 82728 | <1% | 253 | $1K | |
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes | <1% | 16 | $1K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,501 | $1K |
| 72190 | <1% | 12 | $1K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 7,208 | $1K |
| 88346 | <1% | 12 | $1K | |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 28 | $1K |
| 71250 | <1% | 12 | $1K | |
| A4649 | Surgical supply; miscellaneous | <1% | 818 | $1K |
| 83721 | <1% | 100 | $1K | |
| 73560 | <1% | 15 | $1K | |
| 86900 | <1% | 240 | $989.12 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 19,069 | $921.38 |
| 86592 | <1% | 83 | $888.52 | |
| 86703 | <1% | 37 | $872.81 | |
| 86304 | <1% | 49 | $842.88 | |
| 87902 | <1% | 17 | $822.48 | |
| 86706 | <1% | 74 | $807.42 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,991 | $784.44 |
| 93225 | <1% | 16 | $758.19 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 35 | $713.02 |
| 90686 | <1% | 15 | $705.44 | |
| 86704 | <1% | 41 | $703.14 | |
| 73620 | <1% | 16 | $688.79 | |
| 84436 | <1% | 194 | $678.62 | |
| 83540 | <1% | 158 | $654.46 | |
| 87480 | <1% | 319 | $636.71 | |
| 82103 | <1% | 13 | $518.05 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 78 | $517.66 |
| 86901 | <1% | 240 | $492.72 | |
| 85379 | <1% | 28 | $411.60 | |
| 87905 | <1% | 12 | $410.24 | |
| 86480 | <1% | 14 | $375.62 | |
| 82397 | <1% | 24 | $375.50 | |
| 87631 | <1% | 15 | $346.10 | |
| 84703 | <1% | 5,033 | $313.48 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,213 | $276.16 |
| 83615 | <1% | 164 | $265.50 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 145 | $242.30 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 623 | $239.72 |
| 86376 | <1% | 13 | $226.38 | |
| 86708 | <1% | 27 | $214.42 | |
| 86160 | <1% | 29 | $200.01 | |
| Q3014 | Telehealth originating site facility fee | <1% | 119 | $193.78 |
| 86038 | <1% | 25 | $173.45 | |
| 36591 | <1% | 27 | $162.93 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,177 | $133.25 |
| 84550 | <1% | 43 | $132.90 | |
| 86803 | <1% | 25 | $123.20 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,508 | $119.87 |
| 82570 | <1% | 77 | $85.85 | |
| 82947 | <1% | 822 | $81.36 | |
| 82390 | <1% | 12 | $45.77 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 493 | $38.96 |
| 83735 | <1% | 434 | $36.88 | |
| 82077 | <1% | 543 | $28.37 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 383 | $27.97 |
| 87147 | <1% | 104 | $22.22 | |
| J2704 | Injection, propofol, 10 mg | <1% | 9,921 | $6.35 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 37 | $4.74 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,517 | $0.45 |
| 82565 | 0% | 79 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 1,260 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 175 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 173 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 33 | $0.00 |
| 88313 | 0% | 12 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 151 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 93 | $0.00 |
| A4314 | Insertion tray with drainage bag with indwelling catheter, foley type, two-way latex with coating (teflon, silicone, silicone elastomer or hydrophilic, etc.) | 0% | 39 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 13 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 13 | $0.00 |
| 99215 | Doctor's office visit, returning patient (complex) | 0% | 60 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 14 | $0.00 |
| A4222 | Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately) | 0% | 39 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 48 | $0.00 |
| A7002 | Tubing, used with suction pump, each | 0% | 32 | $0.00 |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 0% | 31 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 12 | $0.00 |
| 87186 | 0% | 14 | $0.00 | |
| 96376 | 0% | 319 | $0.00 | |
| C1769 | Guide wire | 0% | 174 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 279 | $0.00 |
| A4217 | Sterile water/saline, 500 ml | 0% | 469 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 190 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 144 | $0.00 |
| 88342 | 0% | 154 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 436 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 74 | $0.00 |
| 88300 | 0% | 38 | $0.00 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 0% | 12 | $0.00 |
| 86308 | 0% | 41 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 114 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 28 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 43 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 45 | $0.00 |
| 83880 | 0% | 16 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 15 | $0.00 |
| 74420 | 0% | 16 | $0.00 | |
| 88304 | 0% | 16 | $0.00 | |
| 87077 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARDEN, GREGORY (CFO)
| Provider | Location | Paid |
|---|---|---|
| Uch-Mhs | Colorado Springs, CO | $2.02M |
| Uch-Mhs | Fountain, CO | $1.52M |
| Uchealth Pikes Peak Regional Hospital | Woodland Park, CO | $1.44M |
| Uchealth Grandview Hospital | Colorado Springs, CO | $331K |
| Uch-Mhs | Colorado Springs, CO | $192K |
| Uch-Mhs | Colorado Springs, CO | $180K |
| Uch-Mhs | Colorado Springs, CO | $59K |
| Uch-Mhs | Colorado Springs, CO | $7K |
| Uch-Mhs | Colorado Springs, CO | $1K |
| Uch-Mhs | Colorado Springs, CO | $82.81 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.